126 related articles for article (PubMed ID: 29477137)
21. Treatment of invasive pulmonary aspergillosis in neutropenic patients by additional bronchoscopic amphotericin B instillation.
Winkler J; Müller U; Nenoff P; Seyfarth HJ; Vogtmann M; Borte G; Pönisch W; Kahn T; Wirtz H; Schauer J; Hoheisel G
Respiration; 2007; 74(6):663-73. PubMed ID: 17622755
[TBL] [Abstract][Full Text] [Related]
22. Intensive intravenous amphotericin B for prophylaxis of systemic fungal infections. Results of a prospective controlled pilot study in acute leukemia patients.
Karthaus M; Doellmann T; Klimasch T; Elser C; Rosenthal C; Ganser A; Heil G
Chemotherapy; 2000; 46(4):293-302. PubMed ID: 10859435
[TBL] [Abstract][Full Text] [Related]
23. Low-dose amphotericin for prevention of serious fungal infection following liver transplantation.
Shah T; Lai WK; Gow P; Leeming J; Mutimer D
Transpl Infect Dis; 2005; 7(3-4):126-32. PubMed ID: 16390401
[TBL] [Abstract][Full Text] [Related]
24. Reversal of cancer chemotherapeutic resistance by amphotericin B--A broad phase I-II pilot study.
Presant CA; Multhauf P; Metter G
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):683-7. PubMed ID: 3653189
[TBL] [Abstract][Full Text] [Related]
25. Liposomal amphotericin B for prophylaxis of invasive fungal infections in high-risk paediatric patients with chemotherapy-related neutropenia: interim analysis of a prospective study.
Uhlenbrock S; Zimmermann M; Fegeler W; Jürgens H; Ritter J
Mycoses; 2001 Dec; 44(11-12):455-63. PubMed ID: 11820258
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis.
Sidhu R; Lash DB; Heidari A; Natarajan P; Johnson RH
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686150
[TBL] [Abstract][Full Text] [Related]
27. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations.
Barrett JP; Vardulaki KA; Conlon C; Cooke J; Daza-Ramirez P; Evans EG; Hawkey PM; Herbrecht R; Marks DI; Moraleda JM; Park GR; Senn SJ; Viscoli C;
Clin Ther; 2003 May; 25(5):1295-320. PubMed ID: 12867214
[TBL] [Abstract][Full Text] [Related]
28. AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.
Lawrence DS; Youssouf N; Molloy SF; Alanio A; Alufandika M; Boulware DR; Boyer-Chammard T; Chen T; Dromer F; Hlupeni A; Hope W; Hosseinipour MC; Kanyama C; Lortholary O; Loyse A; Meya DB; Mosepele M; Muzoora C; Mwandumba HC; Ndhlovu CE; Niessen L; Schutz C; Stott KE; Wang D; Lalloo DG; Meintjes G; Jaffar S; Harrison TS; Jarvis JN
Trials; 2018 Nov; 19(1):649. PubMed ID: 30470259
[TBL] [Abstract][Full Text] [Related]
29. A retrospective study on the efficacy and safety of amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients.
Torre D; Banfi G; Tambini R; Speranza F; Zeroli C; Martegani R; Airoldi M; Fiori G
J Infect; 1998 Jul; 37(1):36-8. PubMed ID: 9733375
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis.
Martín MT; Gavaldà J; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Jordano Q; Ruiz I; Rosal M; Almirante B; Pahissa A
J Antimicrob Chemother; 2003 Dec; 52(6):1032-4. PubMed ID: 14613950
[TBL] [Abstract][Full Text] [Related]
31. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.
Kuti JL; Kotapati S; Williams P; Capitano B; Nightingale CH; Nicolau DP
Pharmacoeconomics; 2004; 22(5):301-10. PubMed ID: 15061680
[TBL] [Abstract][Full Text] [Related]
32. Comparative study of the efficacy of liposomal amphotericin B and amphotericin B deoxycholate against six species of Zygomycetes in a murine lethal infection model.
Takemoto K; Yamamoto Y; Kanazawa K
J Infect Chemother; 2010 Dec; 16(6):388-95. PubMed ID: 20535522
[TBL] [Abstract][Full Text] [Related]
33. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.
Cordonnier C; Mohty M; Faucher C; Pautas C; Robin M; Vey N; Monchecourt F; Mahi L; Ribaud P
Int J Antimicrob Agents; 2008 Feb; 31(2):135-41. PubMed ID: 18162375
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of deoxycholate amphotericin B and unilamellar liposomal amphotericin B in prophylaxis of experimental Aspergillus fumigatus endocarditis.
Mylonakis E; Chalevelakis G; Saroglou G; Danias P; Argyropoulou AD; Paniara O; Raptis SA
Mayo Clin Proc; 1997 Nov; 72(11):1022-7. PubMed ID: 9374975
[TBL] [Abstract][Full Text] [Related]
35. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients.
Peleg AY; Woods ML
J Antimicrob Chemother; 2004 Oct; 54(4):803-8. PubMed ID: 15308606
[TBL] [Abstract][Full Text] [Related]
36. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial.
Bicanic T; Wood R; Meintjes G; Rebe K; Brouwer A; Loyse A; Bekker LG; Jaffar S; Harrison T
Clin Infect Dis; 2008 Jul; 47(1):123-30. PubMed ID: 18505387
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of liposomal amphotericin B in patients admitted to the ICU on renal replacement therapy.
Álvarez-Lerma F; Rodriguez M; Soriano MC; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maravi E; Fernández Rey E; Alvarado F; López-Sánchez M; Alvarez-Sánchez B; Granado D; Quintana E;
Rev Esp Quimioter; 2013 Dec; 26(4):360-8. PubMed ID: 24399350
[TBL] [Abstract][Full Text] [Related]
38. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
Mattiuzzi GN; Kantarjian H; Faderl S; Lim J; Kontoyiannis D; Thomas D; Wierda W; Raad I; Garcia-Manero G; Zhou X; Ferrajoli A; Bekele N; Estey E
Cancer; 2004 Feb; 100(3):581-9. PubMed ID: 14745876
[TBL] [Abstract][Full Text] [Related]
39. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients.
Prentice HG; Hann IM; Herbrecht R; Aoun M; Kvaloy S; Catovsky D; Pinkerton CR; Schey SA; Jacobs F; Oakhill A; Stevens RF; Darbyshire PJ; Gibson BE
Br J Haematol; 1997 Sep; 98(3):711-8. PubMed ID: 9332329
[TBL] [Abstract][Full Text] [Related]
40. Continuous infusion of amphotericin B: preliminary experience at Faculdade de Medicina da Fundação ABC.
Uehara RP; Sá VH; Koshimura ET; Prudente FV; Tucunduva LT; Gonçalves MS; Samano ES; del Giglio A
Sao Paulo Med J; 2005 Sep; 123(5):219-22. PubMed ID: 16358096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
